The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Fernando, Maria Ruweka ^a   Reyes, Jose Luis ^a   Iannuzzi, Jordan ^a   Leung, Gabriella ^a   McKay, Derek Mark ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 4R ALPHA CHAIN; INTERLEUKIN 6; NITRIC OXIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; CHEMOKINE; IL4RA PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WOUND HEALING; ANIMAL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MONOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CHEMOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MONOCYTES; PHENOTYPE; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; UP-REGULATION;

EID: 84899676659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094188     Document Type: Article

References (38)

1. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
2. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35. (Pubitemid 37328697)
3. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686. (Pubitemid 39457982)
4. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
5. Horsnell WG, Brombacher F (2010) Genes associated with alternatively activated macrophages discretely regulate helminth infection and pathogenesis in experimental mouse models. Immunobiology 215: 704-708.
6. Stout RD, Watkins SK, Suttles J (2009) Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 86: 1105- 1109.
7. Stout RD, Suttles J (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 76: 509-513. (Pubitemid 39129080)
8. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342-349. (Pubitemid 40884337)
9. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, et al. (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183: 6469-6477.
10. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, et al. (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173: 781-792.
11. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, et al. (2005) Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 66: 222-230. (Pubitemid 40395242)
12. Nagy ZS, Czimmerer Z, Szanto A, Nagy L (2013) Pro-inflammatory cytokines negatively regulate PPARgamma mediated gene expression in both human and murine macrophages via multiple mechanisms. Immunobiology 218: 1336- 1344.
13. Muzes G, Molnar B, Tulassay Z, Sipos F (2012) Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 18: 5848-5861.
14. Mircic M, Kavanaugh A (2009) The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc) 45: 189-197.
15. Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40: 1830-1835.
16. Classen A, Lloberas J, Celada A (2009) Macrophage activation: classical versus alternative. Methods Mol Biol 531: 29-43.
17. Prescott D, McKay DM (2011) Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 301: 487-497.
18. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108. (Pubitemid 351818697)
19. Smyth D, Leung G, Fernando M, McKay DM (2012) Reduced surface expression of epithelial E-cadherin evoked by interferon-gamma is Fyn kinasedependent. PLoS One 7: e38441.
20. Huber S, Hoffmann R, Muskens F, Voehringer D (2010) Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PDL2. Blood 116: 3311-3320.
21. Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, et al. (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 71: 597-602.
22. Varin A, Mukhopadhyay S, Herbein G, Gordon S (2010) Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood 115: 353-362.
23. Whyte CS, Bishop ET, Ruckerl D, Gaspar-Pereira S, Barker RN, et al. (2011) Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol 90: 845-854.
24. Chomarat P, Banchereau J, Davoust J, Palucka AK (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1: 510-514.
25. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
26. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr., et al. (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116: 2044-2055. (Pubitemid 44033328)
27. Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8: 1237- 1247.
28. Angeli V, Faveeuw C, Delerive P, Fontaine J, Barriera Y, et al. (2001) Schistosoma mansoni induces the synthesis of IL-6 in pulmonary microvascular endothelial cells: role of IL-6 in the control of lung eosinophilia during infection. Eur J Immunol 31: 2751-2761. (Pubitemid 32898743)
29. McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, et al. (2010) Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 184: 7219-7228.
30. Smolen JS, Maini RN (2006) Interleukin-6: A new therapeutic target. Arthritis Res Ther 8 Suppl 2: S5.
31. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320. (Pubitemid 28067327)
32. Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, et al. (2013) In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med 5: 170-115.
33. Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139- 145.
34. Qualls JE, Neale G, Smith AM, Koo MS, DeFreitas AA, et al. (2010) Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci Signal 3: 62.
35. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2: 907- 916. (Pubitemid 32976162)
36. Antignano F, Hamilton M, Patterson S, Ho V, Cohen C, et al. (2011) SHIPdeficient dendritic cells, unlike wild type dendritic cells, suppress T cell proliferation via a nitric oxide-independent mechanism. PLoS One 6: e21893.
37. Kostek MC, Nagaraju K, Pistilli E, Sali A, Lai SH, et al. (2012) IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskelet Disord 13: 106.
38. Guerrero AR, Uchida K, Nakajima H, Watanabe S, Nakamura M, et al. (2012) Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 9: 40.